Editorial
doi: 10.1097/CM9.0000000000001338.
Immunotherapy in non-small cell lung cancer: advancements and challenges
Affiliations
- PMID: 33595975
- PMCID: PMC8143766
- DOI: 10.1097/CM9.0000000000001338
Item in Clipboard
Editorial
Immunotherapy in non-small cell lung cancer: advancements and challenges
Chin Med J (Engl).
.
No abstract available
Conflict of interest statement
None.
Similar articles
-
[Immunotherapy for non-small-cell lung cancer].Rev Prat. 2021 Dec;71(10):1057-1059. Rev Prat. 2021. PMID: 35147356 French. No abstract available.
-
Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm.Eur Respir J. 2020 Feb 6;55(2):1901907. doi: 10.1183/13993003.01907-2019. Print 2020 Feb. Eur Respir J. 2020. PMID: 32029641 No abstract available.
-
Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives.Curr Mol Pharmacol. 2016;9(3):183-195. doi: 10.2174/1874467208666150716120108. Curr Mol Pharmacol. 2016. PMID: 26177648 Review.
-
Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.J Clin Oncol. 2019 Aug 1;37(22):1863-1867. doi: 10.1200/JCO.18.02118. Epub 2019 Apr 17. J Clin Oncol. 2019. PMID: 30995172 No abstract available.
-
Immunologic strategies for the treatment of non-small cell lung cancer.Surgery. 2002 Jan;131(1 Suppl):S232-5. doi: 10.1067/msy.2002.119794. Surgery. 2002. PMID: 11821817 Review. No abstract available.
Cited by
-
Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials.Front Pharmacol. 2022 Nov 10;13:1037620. doi: 10.3389/fphar.2022.1037620. eCollection 2022. Front Pharmacol. 2022. PMID: 36438813 Free PMC article.
-
Prognostic Value of Immunotyping Combined with Targeted Therapy in Patients with Non-Small-Cell Lung Cancer and Establishment of Nomogram Model.Comput Math Methods Med. 2022 May 14;2022:3049619. doi: 10.1155/2022/3049619. eCollection 2022. Comput Math Methods Med. 2022. Retraction in: Comput Math Methods Med. 2023 Oct 18;2023:9839714. doi: 10.1155/2023/9839714. PMID: 35607647 Free PMC article. Retracted.
-
Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer.J Thorac Dis. 2023 Apr 28;15(4):1648-1657. doi: 10.21037/jtd-22-1611. Epub 2023 Mar 28. J Thorac Dis. 2023. PMID: 37197488 Free PMC article.
-
Metformin is a potential therapeutic for COVID-19/LUAD by regulating glucose metabolism.Sci Rep. 2024 May 30;14(1):12406. doi: 10.1038/s41598-024-63081-0. Sci Rep. 2024. PMID: 38811809 Free PMC article.
-
Delayed Separation of Kaplan-Meier Curves is Commonly Observed in Studies of Advanced/Metastatic Solid Tumors Treated with Anti-PD-(L)1 Therapy: Systematic Review and Meta-Analysis.Target Oncol. 2025 Jan;20(1):45-56. doi: 10.1007/s11523-024-01108-2. Epub 2024 Nov 10. Target Oncol. 2025. PMID: 39522075 Free PMC article.
References
-
- Reck M, Rodriguez-Abreu D, Robinson AG, Hui RN, Csoszi T, Fulop A, et al. . Updated Analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019; 37:537–546. doi: 10.1200/Jco.18.00149. - PubMed
-
- Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019; 393:1819–1830. doi: 10.1016/S0140-6736(18)32409-7. - PubMed
-
- Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. . Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378:2078–2092. doi: 10.1056/NEJMoa1801005. - PubMed
-
- Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. . Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378:2288–2301. doi: 10.1056/NEJMoa1716948. - PubMed
-
- Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, et al. . Atezolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer: results from the randomized phase III IMpower132 trial. J Thorac Oncol 2020. doi: 10.1016/j.jtho.2020.11.025. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
